Evercore ISI lowered the firm’s price target on Repligen (RGEN) to $170 from $180 and keeps an Outperform rating on the shares following the company’s Q4 report and FY26 guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen: Solid Execution and Credible Growth Outlook, But Upside Limited at Current Valuation
- Repligen price target lowered to $180 from $190 at Wells Fargo
- Repligen price target lowered to $175 from $200 at Barclays
- Repligen Signals Confident Growth Path In 2026 Outlook
- Repligen: Cautious 2026 Guidance with Derisked Upside and Premium-Valuation Growth Justifying a Buy Rating